Lung Cancer Playlist

Listen to Canadian experts provide their insight into the use of I-O in management of early-stage and advanced NSCLC an MPM. Topics covered include the role of biomarker testing, treatment individualization and sequencing, multidisciplinary collaboration, an toxicity profiles. 

1. How do you choose between neoadjuvant and adjuvant I-O in resectable NSCLC?
    Answered by Dr. Jonathan Spicer

2. What types of biomarker testing and pathology reports are necessary pre- and post-surgery for informed treatment planning? 
    Answered by Dr. Barbara Melosky

3. How do you facilitate multidisciplinary collaboration for treatment planning before and after surgery?
    Answered by Dr. Jonathan Spicer

4. What is the chance that treating NSCLC with I-O and chemotherapy in the neoadjuvant setting could prevent a patient from ever undergoing curative intent surgery?
    Answered by Dr. Jonathan Spicer

5. What are optimal sequencing strategies in the first-line and second-line metastatic NSCLC settings?
    Answered by Dr. Rosalyn Juergens 

6. Which patient factors influence your treatment selection when choosing between dual I-O plus chemotherapy and I-O plus chemotherapy in the first-line metastatic NSCLC setting?
    Answered by Dr. Daniel Breadner and Dr. Kevin Jao 

7. Which disease factors influence your treatment selection when choosing between dual I-O plus chemotherapy and I-O plus chemotherapy in the first-line metastatic NSCLC setting?
    Answered by Dr. Daniel Breadner, Dr. Kevin Jao and Dr. Barbara Melosky

8. In patients with high PD1 expression, what factors would determine whether I-O would be given as monotherapy or in combination with chemotherapy or 9-LA?
    Answered by Dr. Rosalyn Juergens 

9. What treatment would you consider for a non-smoking patient with no driver mutations?
    Answered by Dr. Kevin Jao

10. What is your level of comfort with managing the toxicity associated with dual I-O in metastatic NSCLC?
    Answered by Dr. Kevin Jao and Dr. Barbara Melosky

11. What are optimal sequencing strategies for patients with MPM and do they differ for MPM with epithelioid vs non-epithelioid histology?
    Answered by Dr. Kevin Jao 

 I-O: immuno-oncology - MPM: malignant pleural mesothelioma - NSCLC: non-small cell lung cancer - PD1: programmed cell death protein 1